Nwam LLC Cuts Stock Holdings in CRISPR Therapeutics AG $CRSP

Nwam LLC trimmed its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 39.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 61,843 shares of the company’s stock after selling 39,926 shares during the quarter. Nwam LLC’s holdings in CRISPR Therapeutics were worth $3,380,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Capital International Investors boosted its holdings in CRISPR Therapeutics by 1.0% during the 3rd quarter. Capital International Investors now owns 5,649,258 shares of the company’s stock worth $366,128,000 after acquiring an additional 55,511 shares during the last quarter. State Street Corp boosted its holdings in CRISPR Therapeutics by 35.6% during the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after acquiring an additional 859,334 shares during the last quarter. Orbis Allan Gray Ltd boosted its holdings in CRISPR Therapeutics by 76.9% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after acquiring an additional 1,201,600 shares during the last quarter. UBS Group AG boosted its holdings in CRISPR Therapeutics by 7.7% during the 4th quarter. UBS Group AG now owns 2,524,144 shares of the company’s stock worth $132,366,000 after acquiring an additional 180,580 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in CRISPR Therapeutics by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,364,645 shares of the company’s stock worth $153,253,000 after acquiring an additional 66,556 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: HC Wainwright and Brookline Capital Markets both raised several near-term earnings estimates for CRSP, signaling slightly better expectations for 2026 and 2027 profitability. Those revisions can help support the stock by suggesting improving fundamentals. Analyst estimate updates for CRISPR Therapeutics
• Positive Sentiment: Piper Sandler reiterated a Buy view on CRSP, adding to the constructive analyst tone around the name. Piper Sandler Buy rating article
• Neutral Sentiment: CRISPR Therapeutics was also listed as a “trending stock” on Zacks, which reflects elevated investor interest but does not by itself change the company’s outlook. CRISPR Therapeutics trending stock article
• Neutral Sentiment: One note highlighted conflicting analyst sentiment across healthcare names, reinforcing that CRSP is still viewed as a high-uncertainty biotech story rather than a clear fundamentals-driven winner. Conflicting analyst sentiment article
• Negative Sentiment: Despite some upgrades, the company is still expected to post meaningful losses in the coming years, and Brookline cut its FY2026 and FY2030 earnings outlook in some areas, reminding investors that CRSP remains a speculative, pre-profitability story. CRISPR Therapeutics earnings estimate updates

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,150 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $152,019.00. Following the sale, the insider directly owned 13,143 shares in the company, valued at approximately $634,281.18. The trade was a 19.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 10,020 shares of the business’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the completion of the sale, the chief executive officer owned 255,501 shares in the company, valued at $11,952,336.78. This represents a 3.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 51,828 shares of company stock worth $2,578,097. Company insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on CRSP shares. Bank of America cut their price objective on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Piper Sandler reiterated an “overweight” rating and set a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Evercore reiterated an “outperform” rating and set a $74.00 target price on shares of CRISPR Therapeutics in a research note on Friday, February 13th. Finally, Morgan Stanley reiterated an “underweight” rating and set a $33.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $65.94.

CRISPR Therapeutics Trading Up 4.6%

Shares of CRISPR Therapeutics stock opened at $54.83 on Friday. CRISPR Therapeutics AG has a 52-week low of $34.87 and a 52-week high of $78.48. The stock’s 50-day simple moving average is $52.34 and its 200 day simple moving average is $54.39. The stock has a market capitalization of $5.29 billion, a P/E ratio of -8.82 and a beta of 1.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 13.32 and a current ratio of 17.97.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The firm had revenue of $1.46 million during the quarter. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -5.07 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.